Calliditas has presented the initial results from the Part B study featuring the 15m follow-up period after using the initial Tarpeyo treatment (the 9m active period). The overall results confirm that the positive proteinuria (UPCR) effect (a surrogate marker demonstrating the earlier recorded positive impact after 9m and 12m) improved to -34% after 24 months vs -5% for placebo. The more important part is Tarpeyo’s ability to address declining kidney function (eGFR filtration). The overall effect confirms the Part A result. After two years, the eGFR vs placebo was, on average, 5.05 mL/min/1.73 m2 better in the active group over the 24m period, and the impact of the eGFR benefit was observed across the patient group. We expect a positive reaction on the back of the initial results.